At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 365 enrolled
Drug / intervention
RAD001(everolimus) +2 moredrug
Likely dose
RAD001(everolimus) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney
In Brief
A Phase 2 clinical trial evaluating RAD001(everolimus), interferon alfa-2a, and 1 other intervention for Carcinoma and 4 related conditions. Completed, enrolled 365 participants across 109 sites in 21 countries.
Detailed Summary
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma, Hypernephroid
CountriesBelgium, Brazil, Czechia, Egypt, France, Germany, Hong Kong, Hungary, Italy, Netherlands, Russia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States
CollaboratorsRoche Pharma AG
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartNov 2008
Primary CompletionDec 2011
Study CompletionApr 2013
TodayJul 2026
First PostedJul 21, 2008
Enrollment StartNov 12, 2008
Primary CompletionDec 31, 2011
Study CompletionApr 15, 2013
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.9 years ago
Interventions
RAD001(everolimus)drug
10 mg qd
interferon alfa-2adrug
dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
bevacizumabdrug
10 mg/kg every 2 weeks